Multiple Myeloma, Cancer News Articles

Multiple Myeloma News

MULTIPLE MYELOMA ADVISOR

Multiple Myeloma News

Belantamab Mafodotin Gets Priority Review for Heavily Pretreated Multiple Myeloma

The FDA has granted Priority Review to the Biologics License Application (BLA) of belantamab mafodotin (GSK2857916; GlaxoSmithKline) for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.
Next post in Multiple Myeloma News